长春瑞滨和卡铂联合同步放疗治疗晚期非小细胞肺癌观察  

Homemade vinorelbine based chemotherapy and concurrent radiotherapy in locally advanced non-small-cell lung cancer

作　　者：张中民[1] 赵海燕[1] 张传建[1] 牟建国[1] 

机构地区：[1]临沂市人民医院放疗中心,山东临沂276003

出　　处：《临床肿瘤学杂志》2004年第6期625-627,共3页Chinese Clinical Oncology

摘　　要：目的 :评价国产长春瑞滨 (盖诺 )和卡铂联合同步放疗治疗晚期非小细胞肺癌的疗效及毒副反应。方法 :10 6例Ⅲ期NSCLC患者 ,分为二组 ,化放组在放疗的同时及放疗后进行 4周期化疗 ,化疗用药盖诺 2 5mg/m2 在每个周期的第 1、8天静脉滴注给予 ;卡铂 30 0mg/m2 第 1天静脉滴注。单放组行单纯放疗。结果 :化放组有效率 71 4 % ,单放组有效率为4 2 0 %。化放组的有效率明显高于单放组 (P =0 0 0 8)。化放组和单放组的 1、2年生存率分别为 77 39%、30 33%和5 8 6 5 %、15 75 % ,中位生存时间分别为 18个月和 13个月 ,其差异有显著性 (P =0 0 4 0 7)。结论 :盖诺和卡铂联合同步放疗是治疗晚期非小细胞肺癌的安全有效的治疗方法 。Objective:To evaluate the treatment outcome and toxicity of vinorelbine based chemotherapy and concurrent radiotherapy in Stage Ⅲ non-small-cell lung cancer.Methods:106 patients were divided randomly into the following groups:group 1 was given to a total dose of 60 GY radiotherapy and four cycles of concurrent chemotherapy(vinorelbine 25 mg/m 2 on Days 1,8,29,36,57,64,85 and 92.carboplatin 300 mg/m 2 on Days 1,29,57 and 85 ).Group 2 was given to a total dose of 60 GY radiotherapy alone.Results:The response rate was 71.4% for group 1 and 42.0% for gruop 2,respectively (P=0.008).The survival rate was 77.39% at 1 year,30.33% at 2 years,the median survival was 18 months for group 1 and compared with 58.65%,15.75%,13 months for group 2,respectively (P=0.0407).Conclusion:Homemade vinorelbine based chemotherapy and concurrent radiotherapy,as described here,is a well-tolerated regimen with acceptable toxicity.More effective treatment schemes are required to improve disease control and overall survival.

关 键 词：卡铂 治疗 晚期非小细胞肺癌 同步放疗 联合 盖诺 长春瑞滨 有效率 静脉滴注 化疗 

分 类 号：R734[医药卫生—肿瘤] R735[医药卫生—临床医学]